|[March 27, 2014]
SeeThruEquity Initiates Research Coverage on NanoViricides, Inc.
NEW YORK --(Business Wire)--
SeeThruEquity, a leading independent equity research and corporate
access firm focused on smallcap and microcap public companies, today
announced that it has initiated coverage on NanoViricides, Inc.
(NYSE-MKT:NNVC), a development stage company that is creating special
purpose nanomaterials for viral therapy.
"Unlike a typical emerging biotechnology company with one, or maybe two,
lead drug candidates with blockbuster market potential, NanoViricides
can use their technology to target numerous drug categories. They are
initially developing Injectable FluCide™ for hospitalized patients being
treated for all influenzas. This represents a $25bn annual market
opportunity," remarked Ajay Tandon, CEO of SeeThruEquity. "We are
initiating coverage with a fair value estimate of $7.21 per share."
The note is available to SeeThruEquity
Select Members on SeeThruEquity's
website and can be directly accessed here: NNVC
Initiation Report. SeeThruEquity is an approved equity research
contributor on Thomson (News - Alert) First Call, Capital IQ, FactSet, and Zack's. The
note will also be available on these platforms.
Please review important disclosures on our website at www.seethruequity.com.
SeeThruEquity is an equity research and corporate access firm focused on
companies with less than $1 billion in market capitalization. The
research is not paid for and�unbiased. We do not conduct any investment
banking or commission based business. We are approved to contribute our
research to Thomson One Analytics (First Call), Capital IQ, FactSet (News - Alert),
Zacks and distribute our research to our database of opt-in investors.
We also contribute our estimates to Thomson Estimates, the leading
estimates platform on Wall Street.
For more information visit www.seethruequity.com.
About NanoViricides, Inc.
NanoViricides is a development stage company that is creating special
purpose nanomaterials for viral therapy. The Company's novel
nanoviricide® class of drug candidates are designed to specifically
attack enveloped virus particles and to dismantle them. The Company is
developing drugs against a number of viral diseases including H1N1 swine
flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes,
viral diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others. For more
information, please go to www.NanoViricides.com.
[ InfoTech Spotlight's Homepage ]